Volume | 10,831 |
|
|||||
News | - | ||||||
Day High | 4.81 | Low High |
|||||
Day Low | 4.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.36 | 4.36 | 4.81 | 4.43 | 4.37 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
159 | 10,831 | $ 4.68 | $ 50,645 | - | 3.52 - 18.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:54:13 | 3 | $ 4.44 | USD |
GT Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.12M | 1.38M | - | 0 | -20.88M | -15.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GT Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.16 | 5.21 | 3.81 | 4.52 | 34,871 | 0.27 | 6.49% |
1 Month | 4.35 | 5.21 | 3.81 | 4.65 | 18,034 | 0.08 | 1.84% |
3 Months | 7.80 | 7.803 | 3.52 | 6.23 | 72,114 | -3.37 | -43.21% |
6 Months | 7.368 | 9.90 | 3.52 | 6.98 | 98,432 | -2.94 | -39.88% |
1 Year | 18.00 | 18.00 | 3.52 | 8.91 | 241,671 | -13.57 | -75.39% |
3 Years | 210.00 | 591.993 | 3.52 | 152.29 | 235,777 | -205.57 | -97.89% |
5 Years | 165.00 | 591.993 | 3.52 | 154.46 | 251,241 | -160.57 | -97.32% |
GT Biopharma Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |